Episode 504: ASCO 2026 - ADC Drug Development in Urothelial Cancer

from The Uromigos · host The Uromigos

This episode with Gopa Iyer from MSKCC explores the latest advances in antibody drug conjugates (ADCs) in urothelial cancer, including data from EV302, novel ADCs targeting Nectin-4, and sequencing strategies. Experts discuss efficacy, safety, biomarkers, and future directions in bladder cancer treatment.

Episode metadata supplied by the publisher feed · Published May 29, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Episode 504: ASCO 2026 - ADC Drug Development in Urothelial Cancer

0:00 40:32

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Uromigos?

This episode is 40 minutes long.

When was this The Uromigos episode published?

This episode was published on May 29, 2026.

Can I download this The Uromigos episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!